KDR and nonpapillary renal cell carcinoma: As the use of ICIs gained traction based on the results of the aforementioned ccRCC studies, there was increased interest in combining ICIs with VEGFR TKIs in the treatment of advanced ccRCC (see Table 1 for a list of pivotal first-line trials).